《大行报告》大摩相信药明康德(02359.HK)股价30日内将升 评级「增持」
摩根士丹利发表技术分析报告,相信药明康德(02359.HK)股价30日内将升,发生此机会率料70%至80%,予其股份「增持」评级,目标价155元。
该行表示,药明康德股价於昨日(18日)下跌了8.2%,对比同日恒指为上升0.5%,股价下挫估计或因市场对中国药品委托开发生产服务(CDMO),及集团与客户之间在市场授权持有人(MAH)权利方面的关系感到忧虑。此外,市场亦可能忧虑辉瑞(PFE.US)及Moderna(MRNA.US)等药厂将推出疫苗,或有效控制新型肺炎疫情,令相关治疗的外包可能放缓。
不过,大摩认为,药明康德主要从事小分子研发及生产外包,疫情相关项目并非主要推动力。另外,由於委托生产(CMO)及实验室服务重启,集团今年第三季表现远胜预期,因此该行视是次股价回调为不必要,且为良好的买入机会。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.